- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-07-01-2022
The True Nature of Danger Behind IP Waiver Proposal
July 08, 2022
Back Page
42
7
Issue represents a potential threat in fighting future pandemics.
In DOJ Crosshairs: Rethinking Commission-Based Deals With Independent Contractors
July 08, 2022
Features
42
7
Pharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.
Cracking Down on Speaker Programs
July 08, 2022
Features
42
7
With heightened government scrutiny on educational forums, biopharma manufacturers need a sound framework that demonstrates they are following best practices.
Dynamic Compliance: The Best Defense for Pharma
July 08, 2022
Features
42
7
A proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
July 08, 2022
Features
42
7
COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog.
Breaking Down Barriers
July 08, 2022
Executive Profile
42
7
Dealing with discrimination and bias throughout her career, Otsuka Pharmaceutical’s Christine Sakdalan has forged a strong leadership path built around a two-pronged mission—finding true meaning in the patient journey through market research and data analytics, and mentoring and supporting the development of today’s aspiring professionals.
Biotech Performance Glance—and Promising Ripples for Recovery
July 08, 2022
Finance
42
7
A summary of key takeaways from EY’s new Beyond Borders report.
If Non-Formulary Hospital, Price May Not Be the Rx
July 08, 2022
Managed Markets
42
7
Reversing non-formulary status will usually require new data.
When It Comes To DE&I, Silence Is Deafening
July 08, 2022
DE&I
42
7
For industries like pharma, company voices are vital to building trust.
Asia’s Rise in The Global Pharma Industry
July 08, 2022
APAC
42
7
Continent has shed its ‘emerging’ status on world biopharma stage.
Rewriting European Regulations on Rare Disease Treatments
July 08, 2022
Europe Report
42
7
Legislative-reform alliance makes for strange bedfellows.
Pharmaceutical Executive, July 2022 Issue (PDF)
July 07, 2022
Issue PDF
42
7
Click the title above for a link to open the Pharmaceutical Executive July 2022 issue in an interactive PDF format.
Orphan Drugs: From Niche to Mainstream
June 15, 2022
Features
42
7
Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.
FDA Advances Quality Initiatives to Combat Drug Shortages
June 06, 2022
Washington Report
42
7
Agency again pursuing manufacturer rating system.